AsianScientist (Apr. 8, 2016) – The cancer treatment drug imatinib, otherwise known as Gleevec, is approved to treat chronic myeloid leukemia and some other forms of cancer. However, researchers have stumbled onto another possible use for it—treating type 2 diabetes. Their findings were published in Diabetes.
The team of scientists from Seoul National University and Ulsan National Institute of Science and Technology (UNIST) has identified for the first time that Gleevec lowers the level of insulin resistance, thereby reducing the risk of both hyperglycemia and obesity.
Among insulin-sensitizing drugs, thiazolidinediones (TZD) are a therapeutic class that are selective agonists for PPARγ, which plays a central role in how the body metabolizes glucose, stores fat, and controls immune and inflammatory responses.
“Although TZD-based medicines work effectively at improving glucose uptake by skeletal muscle and other peripheral tissues, due to increased risk of adverse effects, they have been withdrawn from the market,” said study team leader Professor Choi Jang Hyun from the School of Life Sciences at UNIST.
“In order to develop new type of medications that have fewer side effects, we have have discovered a new compound that can maintain stable blood sugar levels.”
In the study, the team observed that the phosphorylation of PPARγ is closely related to developing diabetes. They also discovered that the removal of phosphoric acid from PPARγ shows anti-diabetic effects.
To determine whether phosphoric acid is bound to PPARγ, the team developed a new chemical screening procedure. Using high throughput phosphorylation screening, the team discovered that Gleevec blocks CDK5-mediated PPARγ phosphorylation devoid of classical agonism as a PPARγ antagonist ligand.
“Although studies have shown that Gleevec treatment may show improved insulin sensitivity and decrease blood glucose in patients with known diabetes, the exact cause hasn’t been proven yet,” said Choi.
“Through this research, we discovered Gleevec, which is used in leukemia medications, can inhibit the phosphorylation of PPARγ.”
Moreover, when tested with high-fat diet-fed mice, Gleevec showed improved insulin sensitivity without causing severe side effects seen with other PPARγ-targeting drugs. The researchers note that Gleevec was also found to reduce lipogenic and gluconeogenic gene expression in liver and improved inflammation in adipose tissues. Increased browning of white adipose tissue and energy expenditure were also seen with Gleevec.
The team noted, “Taken together, Gleevec exhibits greater beneficial effects on both glucose/lipid metabolism and energy homeostasis by blocking PPARγ phosphorylation. These data illustrate that Gleevec could be a novel therapeutic agent for use in insulin resistance and type 2 diabetes.”
The article can be found at: Choi et al. (2016) PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue.
———
Source: Ulsan National Institute of Science and Technology; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
